Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 3
2021 4
2022 16
2023 23
2024 51
2025 75
2026 44

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
PURPOSE: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up to every-16-w …
PURPOSE: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A path …
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Agostini H, Abreu F, Baumal CR, Chang DS, G Csaky K, Demetriades AM, Kodjikian L, Lim JI, Margaron P, Monés JM, Peto T, Ricci F, Rüth M, Singh RP, Stoilov I, Swaminathan B, Willis JR, Westenskow PD. Agostini H, et al. Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3437-3451. doi: 10.1007/s00417-024-06531-9. Epub 2024 Jun 7. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38847896 Free PMC article. Review.
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); however, vision gains and anatomical improvements are not sustained ov …
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema …
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S, Wichrowska M, Kocięcki J. Liberski S, et al. Int J Mol Sci. 2022 Aug 20;23(16):9424. doi: 10.3390/ijms23169424. Int J Mol Sci. 2022. PMID: 36012690 Free PMC article. Review.
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular diseases responsible for most blindness in the working-age and older population in developed countries. ...Currently, the Ang/Tie-2 pathway …
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular …
Efficacy and Safety of Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Meta-Analysis.
Nichani PAH, Popovic MM, Mihalache A, Pathak A, Muni RH, Wong DTW, Kertes PJ. Nichani PAH, et al. Ophthalmologica. 2024;247(5-6):355-372. doi: 10.1159/000541662. Epub 2024 Oct 3. Ophthalmologica. 2024. PMID: 39362194 Free PMC article.
RESULTS: Across 13 studies, in the context of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), 2,226 eyes received anti-VEGF monotherapy and 3,022 received faricimab. ...CONCLUS …
RESULTS: Across 13 studies, in the context of neovascular age-related macular degeneration (nAMD), diabetic macular …
Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
Watkins C, Paulo T, Bührer C, Holekamp NM, Bagijn M. Watkins C, et al. Adv Ther. 2023 Dec;40(12):5204-5221. doi: 10.1007/s12325-023-02675-y. Epub 2023 Sep 26. Adv Ther. 2023. PMID: 37751021 Free PMC article.
INTRODUCTION: A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the comparative efficacy, durability and safety of faricimab, used in a Treat & Extend (T&E) regime with intervals up to every 16 weeks (Q16W), relative to …
INTRODUCTION: A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the comparative efficacy, dura …
IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS.
Jaffe GJ, Deák G, Gibson K, Khurana RN, Nudleman E, Ogura Y, Schmidt-Erfurth U, Wang T, Westenskow PD, Wong D, Yiu G, Willis JR. Jaffe GJ, et al. Retina. 2025 Nov 1;45(11):2003-2011. doi: 10.1097/IAE.0000000000004572. Retina. 2025. PMID: 40668667 Free PMC article. Clinical Trial.
BACKGROUND/PURPOSE: To assess the effects of faricimab versus aflibercept on epiretinal membrane (ERM) formation in eyes with diabetic macular edema. ...CONCLUSION: Risk of ERMs was 52% lower with faricimab Q8W versus aflibercept Q8W over 100 we …
BACKGROUND/PURPOSE: To assess the effects of faricimab versus aflibercept on epiretinal membrane (ERM) formation in eyes with diab …
Clinical trials and real-world studies examining faricimab and high-dose aflibercept for wet age-related macular degeneration and diabetic macular edema.
Kalavar M, Sridhar J. Kalavar M, et al. Curr Opin Ophthalmol. 2025 May 1;36(3):189-198. doi: 10.1097/ICU.0000000000001129. Epub 2025 Feb 12. Curr Opin Ophthalmol. 2025. PMID: 39937692 Review.
PURPOSE OF REVIEW: The goal of this review is to summarize emerging clinical trial and real world evidence for faricimab and high dose aflibercept (8 mg), two recently approved treatments for wet age-related macular degeneration and diabetic macular …
PURPOSE OF REVIEW: The goal of this review is to summarize emerging clinical trial and real world evidence for faricimab and high dos …
Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.
Sheth VS, Schlottmann P, Lai TYY, Abreu F, Chang A, Eter N, Gibson K, Hu AY, Korobelnik JF, Kotak A, Kotecha A, O'Leary OE, Pearce I, Sim DA, Sun JK, Tang Y, Khanani AM. Sheth VS, et al. Ophthalmology. 2026 May;133(5):599-612. doi: 10.1016/j.ophtha.2026.01.001. Epub 2026 Jan 12. Ophthalmology. 2026. PMID: 41534798 Free article. Clinical Trial.
PURPOSE: The RHONE-X study (ClinicalTrials.gov identifier, NCT04432831) evaluated long-term safety and tolerability (primary end points), and efficacy (exploratory end points) of faricimab, a dual angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) inh …
PURPOSE: The RHONE-X study (ClinicalTrials.gov identifier, NCT04432831) evaluated long-term safety and tolerability (primary end points), an …
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema.
Lim JI, Amador MJ, Dhoot DS, Finn A, Fraser-Bell S, Gibson K, Idowu OO, Khurana RN, Lanzetta P, Lin TC, Mar FA, Pollreisz A, Rachitskaya A, Schlottmann PG, Tang Y, Lai TYY. Lim JI, et al. Ophthalmol Retina. 2025 Jul;9(7):655-666. doi: 10.1016/j.oret.2025.01.017. Epub 2025 Feb 4. Ophthalmol Retina. 2025. PMID: 39914485 Free PMC article. Clinical Trial.
PURPOSE: To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and aflibercept in a pooled analysis of results from the YOSEMITE/RHINE trials in diabetic macular edema (DME). ...METHODS …
PURPOSE: To compare anatomic biomarkers on spectral-domain OCT between faricimab, a dual angiopoietin-2 (Ang-2)/VEGF-A inhibitor, and …
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, Hershberger VS, Pauly-Evers M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Osborne A, Weikert R, Fauser S. Sahni J, et al. Ophthalmology. 2019 Aug;126(8):1155-1170. doi: 10.1016/j.ophtha.2019.03.023. Epub 2019 Mar 21. Ophthalmology. 2019. PMID: 30905643 Free article. Clinical Trial.
PURPOSE: The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME). ...M …
PURPOSE: The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 …
202 results